Literature DB >> 22541858

Leukocyte chemoattractant receptor FPR2 may accelerate atherogenesis.

Wuzhou Wan1, Ji-Liang Gao.   

Abstract

Atherosclerosis is a chronic inflammatory disease and the number one cause of mortality worldwide. The fundamental causes of atherosclerosis have not been precisely delineated, although pathogenesis clearly involves endothelial dysfunction and both innate and adaptive immunity. Recent evidence suggests that formyl peptide receptor 2 (FPR2), a G protein-coupled receptor (GPCR), mediates a range of inflammatory responses including superoxide production in neutrophils, chemotaxis of monocytes and neutrophils, CCL2 production in endothelial cells (ECs) and monocytes, and increased CXCL8 expression in neutrophils, which are all related with atherogenesis. Therefore, we propose that FPR2 may play a pathogenic role in atherogenesis. Published by Elsevier Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22541858      PMCID: PMC3361548          DOI: 10.1016/j.mehy.2012.04.014

Source DB:  PubMed          Journal:  Med Hypotheses        ISSN: 0306-9877            Impact factor:   1.538


  18 in total

1.  Heart disease and stroke statistics--2012 update: a report from the American Heart Association.

Authors:  Véronique L Roger; Alan S Go; Donald M Lloyd-Jones; Emelia J Benjamin; Jarett D Berry; William B Borden; Dawn M Bravata; Shifan Dai; Earl S Ford; Caroline S Fox; Heather J Fullerton; Cathleen Gillespie; Susan M Hailpern; John A Heit; Virginia J Howard; Brett M Kissela; Steven J Kittner; Daniel T Lackland; Judith H Lichtman; Lynda D Lisabeth; Diane M Makuc; Gregory M Marcus; Ariane Marelli; David B Matchar; Claudia S Moy; Dariush Mozaffarian; Michael E Mussolino; Graham Nichol; Nina P Paynter; Elsayed Z Soliman; Paul D Sorlie; Nona Sotoodehnia; Tanya N Turan; Salim S Virani; Nathan D Wong; Daniel Woo; Melanie B Turner
Journal:  Circulation       Date:  2011-12-15       Impact factor: 29.690

Review 2.  Therapeutic implications of chemokine-mediated pathways in atherosclerosis: realistic perspectives and utopias.

Authors:  Stavros Apostolakis; Virginia Amanatidou; Demetrios A Spandidos
Journal:  Acta Pharmacol Sin       Date:  2010-08-16       Impact factor: 6.150

3.  Serum amyloid A is a better predictor of clinical outcomes than C-reactive protein in non-ST-segment elevation acute coronary syndromes.

Authors:  Masami Kosuge; Toshiaki Ebina; Toshiyuki Ishikawa; Kiyoshi Hibi; Kengo Tsukahara; Jyun Okuda; Noriaki Iwahashi; Hiroyuki Ozaki; Hideto Yano; Ikuyoshi Kusama; Tastuya Nakati; Satoshi Umemura; Kazuo Kimura
Journal:  Circ J       Date:  2007-02       Impact factor: 2.993

4.  NADPH oxidases and atherosclerosis: unraveling the details.

Authors:  Nageswara R Madamanchi; Marschall S Runge
Journal:  Am J Physiol Heart Circ Physiol       Date:  2009-11-06       Impact factor: 4.733

5.  A critical role for the g protein-coupled receptor mFPR2 in airway inflammation and immune responses.

Authors:  Keqiang Chen; Yingying Le; Ying Liu; Wanghua Gong; Guoguang Ying; Jian Huang; Teizo Yoshimura; Lino Tessarollo; Ji Ming Wang
Journal:  J Immunol       Date:  2010-03-03       Impact factor: 5.422

Review 6.  Chemokines in the vascular inflammatory response of atherosclerosis.

Authors:  Alma Zernecke; Christian Weber
Journal:  Cardiovasc Res       Date:  2009-12-09       Impact factor: 10.787

Review 7.  International Union of Basic and Clinical Pharmacology. LXXIII. Nomenclature for the formyl peptide receptor (FPR) family.

Authors:  Richard D Ye; François Boulay; Ji Ming Wang; Claes Dahlgren; Craig Gerard; Marc Parmentier; Charles N Serhan; Philip M Murphy
Journal:  Pharmacol Rev       Date:  2009-06-04       Impact factor: 25.468

8.  Serum amyloid A induces CCL2 production via formyl peptide receptor-like 1-mediated signaling in human monocytes.

Authors:  Ha Young Lee; Sang Doo Kim; Jae Woong Shim; Sun Young Lee; Hwahyung Lee; Kyung-Hyun Cho; Jeanho Yun; Yoe-Sik Bae
Journal:  J Immunol       Date:  2008-09-15       Impact factor: 5.422

Review 9.  Chemokines: established and novel targets in atherosclerosis.

Authors:  Rory R Koenen; Christian Weber
Journal:  EMBO Mol Med       Date:  2011-10-28       Impact factor: 12.137

10.  Anti-inflammatory role of the murine formyl-peptide receptor 2: ligand-specific effects on leukocyte responses and experimental inflammation.

Authors:  Mauro Perretti; Roderick J Flower; Neil Dufton; Robert Hannon; Vincenzo Brancaleone; Jesmond Dalli; Hetal B Patel; Mohini Gray; Fulvio D'Acquisto; Julia C Buckingham
Journal:  J Immunol       Date:  2010-01-27       Impact factor: 5.422

View more
  3 in total

Review 1.  Development of small molecule non-peptide formyl peptide receptor (FPR) ligands and molecular modeling of their recognition.

Authors:  I A Schepetkin; A I Khlebnikov; M P Giovannoni; L N Kirpotina; A Cilibrizzi; M T Quinn
Journal:  Curr Med Chem       Date:  2014       Impact factor: 4.530

Review 2.  The Formyl Peptide Receptors: Diversity of Ligands and Mechanism for Recognition.

Authors:  Hui-Qiong He; Richard D Ye
Journal:  Molecules       Date:  2017-03-13       Impact factor: 4.411

Review 3.  Regulation of Inflammation and Oxidative Stress by Formyl Peptide Receptors in Cardiovascular Disease Progression.

Authors:  Valentina Maria Caso; Valentina Manzo; Tiziana Pecchillo Cimmino; Valeria Conti; Pio Caso; Gabriella Esposito; Vincenzo Russo; Amelia Filippelli; Rosario Ammendola; Fabio Cattaneo
Journal:  Life (Basel)       Date:  2021-03-15
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.